Is there a role for essential fatty acids in osteoporosis?

Journal

European journal of clinical nutrition

ISSN: 1476-5640

Titre abrégé: Eur J Clin Nutr

Pays: England

ID NLM: 8804070

Informations de publication

Date de publication:
05 Jun 2024

Historique:

received: 20 05 2023

accepted: 31 05 2024

revised: 29 05 2024

medline: 6 6 2024

pubmed: 6 6 2024

entrez: 5 6 2024

Statut: aheadofprint

Résumé

Inflammatory markers are inversely associated with bone density, geometry, and strength in postmenopausal women, and elderly subjects suggesting that osteoporosis is a low-grade systemic inflammatory condition. But glucocorticoids that are potent anti-inflammatory compounds instead of arresting/preventing osteoporosis induce osteoporosis. These results indicate that IL-6 and TNF-α, post-menopausal state, and steroids produce osteoporosis by an unidentified mechanism. Pro-inflammatory cytokines, estrogen, and steroids bring about their actions by influencing the metabolism of essential fatty acids (EFAs). I propose that EFAs and their metabolites act as second messengers of actions of corticosteroids, cytokines, and estrogen. This implies that EFAs are of benefit in the prevention and management of osteoporosis. This argument is supported by the observation that plasma phospholipid content of unsaturated fatty acids is decreased in those with osteoporosis. The reports that long-chain metabolites of EFAs including arachidonic acid, docosahexaenoic acid and eicosapentaenoic acid, and lipoxin A4 are of benefit in the prevention and management of osteoporosis lends further support to this proposal.

Identifiants

DOI: 10.1038/s41430-024-01456-2 PMID: 38840032

pubmed: 38840032

doi: 10.1038/s41430-024-01456-2

pii: 10.1038/s41430-024-01456-2

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Arnaud CD. An integrated view of the role of the endocrine system in the genesis of the osteoporosis associated with aging. Osteoporos Int. 1993;3 Suppl.1:37–9.

pubmed: 8461573 doi: 10.1007/BF01621859

Zheng SX, Vrindts Y, Lopez M, De Groote D, Zangerle PF, Collette J, et al. Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas. 1997;26:63–71.

pubmed: 9032749 doi: 10.1016/S0378-5122(96)01080-8

Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology. 1995;136:3054–61.

pubmed: 7789332 doi: 10.1210/endo.136.7.7789332

Qiu J, Lu C, Zhang L, Zhou X, Zou H. Osteoporosis in patients with rheumatoid arthritis is associated with serum immune regulatory cellular factors. Clin Rheumatol. 2022;41:2685–93.

pubmed: 35670881 doi: 10.1007/s10067-022-06212-0

Buchanan WW, Samuels BM, Jasani MK, Anderson JA, O’Brien WM, Boyle JA, et al. Do oral corticosteroids cause osteoporosis in rheumatoid arthritis? Ann Rheum Dis. 1970;29:560–1.

pubmed: 5476686 pmcid: 1010576 doi: 10.1136/ard.29.5.560-b

Madretsma GS, Dijk AP, Tak CJ, Wilson JH, Zijlstra FJ. Inhibition of the production of mediators of inflammation by corticosteroids is a glucocorticoid receptor-mediated process. Mediat Inflamm. 1996;5:100–3.

doi: 10.1155/S0962935196000166

Huang YS, Das UN, Horrobin DF. Effect of dexamethasone on the distribution of essential fatty acids in plasma and liver phospholipids. IRCS Med Sci. 1986;14:10–181.

Manjari V, Das UN. Effect of polyunsaturated fatty acids on dexamethasone-induced gastric mucosal damage. Prostaglandins Leukot Essent Fat Acids. 2000;62:85–96.

doi: 10.1054/plef.1999.0125

Marra CA, de Alaniz MJ, Brenner RR. Modulation of delta 6 and delta 5 rat liver microsomal desaturase activities by dexamethasone-induced factor. Biochim Biophys Acta. 1986;879:388–93.

pubmed: 3778928 doi: 10.1016/0005-2760(86)90230-4

Marra CA, de Alaniz MJ, Brenner RR. Effect of various steroids on the biosynthesis of arachidonic acid in isolated hepatocytes and HTC cells. Lipids. 1988;23:1053–8.

pubmed: 3148796 doi: 10.1007/BF02535651

Das UN. Pro- and anti-inflammatory bioactive lipids imbalance contributes to the pathobiology of autoimmune diseases. Eur J Clin Nutr. 2022. https://doi.org/10.1038/s41430-022-01173-8 .

Das UN. Essential fatty acids and their metabolites in the pathobiology of inflammation and its resolution. Biomolecules. 2021;11:1873.

pubmed: 34944517 pmcid: 8699107 doi: 10.3390/biom11121873

Mayer K, Schmidt R, Muhly-Reinholz M, Bögeholz T, Gokorsch S, Grimminger F, et al. In vitro mimicry of essential fatty acid deficiency in human endothelial cells by TNFalpha impact of omega-3 versus omega-6 fatty acids. J Lipid Res. 2002;43:944–51.

pubmed: 12032170 doi: 10.1016/S0022-2275(20)30469-7

Gundala NKV, Naidu VGM, Das UN. Arachidonic acid and lipoxinA4 attenuate streptozotocin-induced cytotoxicity to RIN5 F cells in vitro and type 1 and type 2 diabetes mellitus in vivo. Nutrition. 2017;35:61–80.

pubmed: 28241993 doi: 10.1016/j.nut.2016.10.004

Bathina S, Gundala NKV, Rhenghachar P, Polavarapu S, Hari AD, Sadananda M, et al. Resolvin D1 ameliorates nicotinamide-streptozotocin-induced type 2 diabetes mellitus by its anti-inflammatory action and modulating PI3K/Akt/mTOR pathway in the brain. Arch Med Res. 2020;51:492–503.

pubmed: 32451116 doi: 10.1016/j.arcmed.2020.05.002

Rengachar P, Polavarapu S, Das UN. Insights in diabetes: molecular mechanisms-Protectin DX, an anti-inflammatory and a stimulator of inflammation resolution metabolite of docosahexaenoic acid, protects against the development of streptozotocin-induced type 1 and type 2 diabetes mellitus in male Swiss albino mice. Front Endocrinol. 2023;13:1053879.

doi: 10.3389/fendo.2022.1053879

Russell R, Gori I, Pellegrini C, Kumar R, Achtari C, Canny GO. Lipoxin A4 is a novel estrogen receptor modulator. FASEB J. 2011;25:4326–37.

pubmed: 21885654 doi: 10.1096/fj.11-187658

Kumar R, Clerc AC, Gori I, Russell R, Pellegrini C, Govender L, et al. Lipoxin A

pubmed: 24587003 pmcid: 3933674 doi: 10.1371/journal.pone.0089742

Das UN. Estrogen, statins, and polyunsaturated fatty acids: similarities in their actions and benefits-is there a common link? Nutrition. 2002;18:178–88.

pubmed: 11844650 doi: 10.1016/S0899-9007(01)00719-5

Liu XH, Kirschenbaum A, Yao S, Levine AC. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology. 2005;146:1991–8.

pubmed: 15618359 doi: 10.1210/en.2004-1167

Das UN. Bioactive lipids as modulators of immune check point inhibitors. Med Hypotheses. 2020;135:109473.

pubmed: 31733534 doi: 10.1016/j.mehy.2019.109473

Das UN. Can bioactive lipid(s) augment anti-cancer action of immunotherapy and prevent cytokine storm? Arch Med Res. 2019;50:342–9.

pubmed: 31677539 doi: 10.1016/j.arcmed.2019.10.004

Liu C, Guan H, Cai C, Li F, Xiao J. Lipoxin A4 suppresses osteoclastogenesis in RAW264.7 cells and prevents ovariectomy-induced bone loss. Exp Cell Res. 2017;352:293–303.

pubmed: 28209487 doi: 10.1016/j.yexcr.2017.02.018

Yang Y, Wang Y, Kong Y, Zhang X, Bai L. The effects of different frequency treadmill exercise on lipoxin A4 and articular cartilage degeneration in an experimental model of monosodium iodoacetate-induced osteoarthritis in rats. PLoS ONE. 2017;12:e0179162.

pubmed: 28594958 pmcid: 5464632 doi: 10.1371/journal.pone.0179162

Wimalawansa SJ, Chapa MT, Yallampalli C, Zhang R, Simmons DJ. Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone. 1997;21:275–80.

pubmed: 9276093 doi: 10.1016/S8756-3282(97)00125-7

Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone. 1996;18:301–4.

pubmed: 8726385 doi: 10.1016/8756-3282(96)00005-1

Pennisi P, D’Alcamo MA, Leonetti C, Clementi A, Cutuli VM, Riccobene S, et al. Supplementation of L-arginine prevents glucocorticoid-induced reduction of bone growth and bone turnover abnormalities in a growing rat model. J Bone Miner Metab. 2005;23:134–9.

pubmed: 15750691 doi: 10.1007/s00774-004-0551-x

Roncero-Martín R, Aliaga I, Moran JM, Puerto-Parejo LM, Rey-Sánchez P, de la Luz Canal-Macías M, et al. Plasma fatty acids and quantitative ultrasound, DXA and pQCT derived parameters in postmenopausal Spanish women. Nutrients. 2021;13:1454.

pubmed: 33922947 pmcid: 8146540 doi: 10.3390/nu13051454

Casado-Díaz A, Santiago-Mora R, Dorado G, Quesada-Gómez JM. The omega-6 arachidonic fatty acid, but not the omega-3 fatty acids, inhibits osteoblastogenesis and induces adipogenesis of human mesenchymal stem cells: potential implication in osteoporosis. Osteoporos Int 2013;24:1647–61.

pubmed: 23104199 doi: 10.1007/s00198-012-2138-z

Coetzee M, Haag M, Joubert AM, Kruger MC. Effects of arachidonic acid, docosahexaenoic acid and prostaglandin E2 on cell proliferation and morphology of MG-63 and MC3T3-E1 osteoblast-like cells. Prostaglandins Leukot Essent Fat Acids. 2007;76:35–45.

doi: 10.1016/j.plefa.2006.10.001

Hogstrom M, Nordström P, Nordström A. N-3 fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO

pubmed: 17344503 doi: 10.1093/ajcn/85.3.803

Virtanen JK, Mozaffarian D, Willett WC, Feskanich D. Dietary intake of polyunsaturated fatty acids and risk of hip fracture in men and women. Osteoporos Int 2012;23:2615–24.

pubmed: 22270860 pmcid: 4213390 doi: 10.1007/s00198-012-1903-3

Bao M, Zhang K, Wei Y, Hua W, Gao Y, Li X, et al. Therapeutic potentials and modulatory mechanisms of fatty acids in bone. Cell Prolif. 2020;53:e12735.

pubmed: 31797479 doi: 10.1111/cpr.12735

Orchard TS, Cauley JA, Frank GC, Neuhouser ML, Robinson JG, Snetselaar L, et al. Fatty acid consumption and risk of fracture in the women’s health initiative. Am J Clin Nutr 2010;92:1452–60.

pubmed: 20980487 pmcid: 2980969 doi: 10.3945/ajcn.2010.29955

Feehan O, Magee PJ, Pourshahidi LK, Armstrong DJ, Slevin MM, Allsopp PJ, et al. Association of long-chain polyunsaturated fatty acids with bone mineral density and bone turnover in postmenopausal women. Eur J Nutr. 2023;62:95–104.

pubmed: 35908118 doi: 10.1007/s00394-022-02933-9

Das UN. “Cell Membrane Theory of Senescence” and the role of bioactive lipids in aging, and aging associated diseases and their therapeutic implications. Biomolecules. 2021;11:241.

pubmed: 33567774 pmcid: 7914625 doi: 10.3390/biom11020241

Ali M, Kucko N, Jansen JA, Yang F, Walboomers XF. The effect of lipoxin A4 on E. coli LPS-induced osteoclastogenesis. Clin Oral Investig. 2021;25:957–69.

pubmed: 32506323 doi: 10.1007/s00784-020-03385-3

Das UN. Ageing: is there a role for arachidonic acid and other bioactive lipids? A review. J Adv Res. 2018;11:67–79.

pubmed: 30034877 pmcid: 6052661 doi: 10.1016/j.jare.2018.02.004

Gyurko R, Van Dyke TE. The role of polyunsaturated ω-3 fatty acid eicosapentaenoic acid-derived resolvin E1 (RvE1) in bone preservation. Crit Rev Immunol. 2014;34:347–57.

pubmed: 24941160 pmcid: 4382917 doi: 10.1615/CritRevImmunol.2014009982

Norling LV, Headland SE, Dalli J, Arnardottir HH, Haworth O, Jones HR, et al. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight. 2016;1:e85922.

pubmed: 27158677 pmcid: 4855303 doi: 10.1172/jci.insight.85922

Das UN. Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation. J Inflamm Res. 2010;3:143–70.

pubmed: 22096364 pmcid: 3218729 doi: 10.2147/JIR.S9425

Boeyens JC, Deepak V, Chua WH, Kruger MC, Joubert AM, Coetzee M. Effects of ω3- and ω6-polyunsaturated fatty acids on RANKL-induced osteoclast differentiation of RAW264.7 cells: a comparative in vitro study. Nutrients. 2014;6:2584–601.

pubmed: 25010555 pmcid: 4113758 doi: 10.3390/nu6072584

Zhu M, Van Dyke TE, Gyurko R. Resolvin E1 regulates osteoclast fusion via DC-STAMP and NFATc1. FASEB J. 2013;27:3344–53.

pubmed: 23629863 pmcid: 3714580 doi: 10.1096/fj.12-220228

Kasonga AE, Deepak V, Kruger MC, Coetzee M. Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14+ monocytes, in vitro. PLoS ONE. 2015;10:e0125145.

pubmed: 25867515 pmcid: 4395026 doi: 10.1371/journal.pone.0125145

Dravid AA, M Dhanabalan K, Agarwal S, Agarwal R. Resolvin D1-loaded nanoliposomes promote M2 macrophage polarization and are effective in the treatment of osteoarthritis. Bioeng Transl Med. 2022;7:e10281.

pubmed: 35600665 pmcid: 9115708 doi: 10.1002/btm2.10281

El Kholy K, Freire M, Chen T, Van Dyke TE. Resolvin E1 promotes bone preservation under inflammatory conditions. Front Immunol. 2018;9:1300.

pubmed: 29946319 pmcid: 6005849 doi: 10.3389/fimmu.2018.01300

Ginaldi L, Di Benedetto MC, De Martinis M. Osteoporosis, inflammation and ageing. Immun Ageing. 2005;2:14.

pubmed: 16271143 pmcid: 1308846 doi: 10.1186/1742-4933-2-14

Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111:1221–30.

pubmed: 12697741 pmcid: 152939 doi: 10.1172/JCI200317215

Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20:795–823.

pubmed: 11861618 doi: 10.1146/annurev.immunol.20.100301.064753

Poulsen RC, Wolber FM, Moughan PJ, Kruger MC. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. Prostaglandins Other Lipid Mediat. 2008;85:42–8.

pubmed: 18077200 doi: 10.1016/j.prostaglandins.2007.10.004